Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Sponsor: Adneuris Therapeutics, Inc.
Summary
The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
Official title: An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-09-22
Completion Date
2027-02
Last Updated
2026-09-30
Healthy Volunteers
No
Conditions
Interventions
Cebranopadol 400 ug
Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Locations (15)
Adneuris Site 001115
Phoenix, Arizona, United States
Adneuris Site 001118
Riverside, California, United States
Adneuris Site 001119
Longmont, Colorado, United States
Adneuris Site 001122
Savannah, Georgia, United States
Adneuris Site 001123
O'Fallon, Illinois, United States
Adneuris Site 001125
Annapolis, Maryland, United States
Adneuris Site 001120
Oradell, New Jersey, United States
Adneuris Site 001124
Tulsa, Oklahoma, United States
Adneuris Site 001110
Bellaire, Texas, United States
Adneuris Site 001117
Forney, Texas, United States
Adneuris Site 001104
McAllen, Texas, United States
Adneuris Site 001116
Plano, Texas, United States
Adneuris Site 001111
San Antonio, Texas, United States
Adneuris Site 001121
San Antonio, Texas, United States
Adneuris Site 001101
Salt Lake City, Utah, United States